Benign Prostatic Hyperplasia Treatment Device Market Size, Share, and Industry Analysis, By Product Type (Resection Devices, Laser Therapy Systems, Minimally Invasive Surgical Therapy (MIST) Devices, and Others), By End-user (Hospitals & ASCs, Specialty Clinics, Interventional Radiology Centers, and Others), and Regional Forecast 2026-2034

The benign prostatic hyperplasia treatment device market size was valued at USD 1.71 billion in 2025 and is expected to reach a market valuation of USD 1.85 billion in 2026. Furthermore, the market is projected to reach a market valuation of USD 3.46 billion by 2034, exhibiting a CAGR of 8.1% during the forecast period.

The increasing adoption of new technologies, such as the prostatic urethral lift, water vapor therapy, and aquablation, in selected patient populations is driving demand for benign prostatic hyperplasia (BPH) treatment devices.

Benign Prostatic Hyperplasia Treatment Device Market Driver

Rising Cases of Benign Prostatic Hyperplasia to Drive the Market Growth

In recent years, there have been a growing cases of benign prostatic hyperplasia, especially in the aging population, which is driving the demand for minimally invasive surgical therapy (MIST) devices, laser therapy systems, resection devices, and others. This is expected to drive global market growth in the forthcoming years.

• For instance, according to a Springer Nature Limited article published in February 2025, around 45.0% of men over age 45 develop BPH, with prevalence climbing to roughly 80.0% in those over 70.

Download Free sample to learn more about this report.

According to data published by the National Center for Biotechnology Information (NCBI) in February 2025, the global incidence and prevalence are expected to increase from 962.42 (incidence) and 7,878.68 (prevalence) per 100,000 population in 2022 to 998.55 and 8,620.60 per 100,000 population in 2035, respectively.

Benign Prostatic Hyperplasia Treatment Device Market Restraint

High Capital Equipment Costs to Hamper the Market Growth

Laser platforms, robotic waterjet systems, and advanced energy-based devices require significant upfront capital investment and continuous maintenance costs, which are expected to limit their adoption in price-sensitive markets. Moreover, the high costs of several therapies are expected to hinder market growth in the coming years.

• For instance, according to the data from Booking Health GmbH, the transurethral microwave therapy treatment costs begin at USD 9,010.2 in Europe.

Benign Prostatic Hyperplasia Treatment Device Market Opportunity

Expansion in Emerging Markets to Offer Lucrative Growth Opportunity

In recent years, several emerging countries, such as China, India, Southeast Asia, and Latin America, have been witnessing the development of urology infrastructure, increased awareness of minimally invasive therapies, and expanding private healthcare spending. This is offering significant growth opportunities for key players to expand their product offerings in these markets.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence/Incidence of Benign Prostatic Hyperplasia, by Countries/Region, 2025
• Technological Advancements in Benign Prostatic Hyperplasia Treatment Devices
• Key Industry Developments - (Partnerships, Mergers, and Acquisitions, etc.)

Analysis by Product Type

By product type, the market is segmented into resection devices, laser therapy systems, minimally invasive surgical therapy (MIST) devices, and others.

The laser therapy systems segment is expected to hold the major share of the global market during the forecast period. These systems are considered the gold standard alternative to TURP. They are expected to drive strong adoption in developed markets such as the U.S., Germany, and Japan, fueling the segment’s growth.

Analysis by End-user

Based on end-user, the market is divided into hospitals & ASCs, specialty clinics, interventional radiology centers, and others.

The hospitals & ASCs segment is expected to hold the largest share of the global market during the forecast period. These settings account for the majority of high-complexity cases and provide favorable reimbursement deals, which support the adoption of treatment therapies and devices. Also, the strong hospital network in several countries is expected to support the segment’s growth.

• For instance, according to data from the State Council of the People’s Republic of China, the country had over 38,000 hospitals in 2023, with public hospitals accounting for less than a third of the total.

Regional Analysis

Request for Customization   to gain extensive market insights.

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for a 41.3 % share of the global benign prostatic hyperplasia treatment device market in 2025. The region's growth is attributed to a strong network of urology clinics, ASCs, and key professionals that support the adoption of BPH treatment devices.

• For instance, in 2023, the American Urological Association reported that the number of practicing urologists in the U.S. reached 14,176, a 1.4% increase from 2022.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The region’s growth is attributed to increasing investments in developing healthcare infrastructure and a larger patient pool, which are anticipated to fuel the adoption of benign prostatic hyperplasia treatment devices.

Key Players Covered

The global benign prostatic hyperplasia treatment device market is highly fragmented, with several key players driven by strong portfolio breadth and geographic expansion initiatives.

The report includes the profiles of the following key players:

• PROCEPT BioRobotics Corporation (U.S.)
• Teleflex Incorporated (U.S.)
• Olympus Corporation (Japan)
• Richard Wolf GmbH (Germany)
• KARL STORZ SE & Co. KG (Germany)
• Biolitec AG (Germany)
• Boston Scientific Corporation (U.S.)
• Dornier MedTech (Germany)
• Urotronic (U.S.)
• Quanta System (Italy)

Key Industry Developments

• November 2025: Olympus Corporation unveiled a new corporate strategy focused on transforming endoscopy-enabled care through innovation in AI, robotics, and cloud solutions, while simplifying operations for global MedTech leadership.
• April 2025: Rivermark Medical enrolled the first patient in the pivotal RAPID-III clinical trial, evaluating the safety and effectiveness of the FloStent System for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).